CA2303901A1 - Use of d-methionine to reduce the toxicity of ototoxic drugs, noise, and radiation - Google Patents

Use of d-methionine to reduce the toxicity of ototoxic drugs, noise, and radiation Download PDF

Info

Publication number
CA2303901A1
CA2303901A1 CA002303901A CA2303901A CA2303901A1 CA 2303901 A1 CA2303901 A1 CA 2303901A1 CA 002303901 A CA002303901 A CA 002303901A CA 2303901 A CA2303901 A CA 2303901A CA 2303901 A1 CA2303901 A1 CA 2303901A1
Authority
CA
Canada
Prior art keywords
radiation
noise
methionine
methods
platinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002303901A
Other languages
French (fr)
Other versions
CA2303901C (en
Inventor
Kathleen C.M. Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Illinois University System
Original Assignee
Southern Illinois University
Kathleen C.M. Campbell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Illinois University, Kathleen C.M. Campbell filed Critical Southern Illinois University
Publication of CA2303901A1 publication Critical patent/CA2303901A1/en
Application granted granted Critical
Publication of CA2303901C publication Critical patent/CA2303901C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods of preventing or reducing hearing or balance loss, damage to ear cells, weight loss, gastrointestinal toxicity, neurotoxicity, alopecia, and prolonging survival in patients undergoing treatment with therapeutically effective amounts of platinum-containing chemotherapeutic agents such as cisplatin are provided. Methods are also provided for preventing or reducing such symptoms in patients undergoing treatment with loop diuretics, aminoglycoside antibiotics, iron chelating agents, quinine, and quinidine, or those who have been exposed to toxic levels of noise or radiation. These methods comprise administering an effective amount of a methionine protective agent, such as D-methionine, prior to, simultaneously with, or subsequently to administration of the platinum-containing chemotherapeutic agent, loop diuretic agent, etc., or exposure to noise or radiation. Combinations of these time periods can also be employed.
CA002303901A 1997-10-02 1998-04-08 Use of d-methionine to reduce the toxicity of ototoxic drugs, noise, and radiation Expired - Fee Related CA2303901C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/942,845 US6187817B1 (en) 1996-10-03 1997-10-02 Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US08/942,845 1997-10-02
PCT/US1998/006960 WO1999017765A1 (en) 1997-10-02 1998-04-08 Use of d-methionine to reduce the toxicity of ototoxic drugs, noise, and radiation

Publications (2)

Publication Number Publication Date
CA2303901A1 true CA2303901A1 (en) 1999-04-15
CA2303901C CA2303901C (en) 2008-09-09

Family

ID=25478684

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303901A Expired - Fee Related CA2303901C (en) 1997-10-02 1998-04-08 Use of d-methionine to reduce the toxicity of ototoxic drugs, noise, and radiation

Country Status (10)

Country Link
US (2) US6187817B1 (en)
EP (1) EP1019036B1 (en)
JP (1) JP2001518499A (en)
AT (1) ATE243511T1 (en)
AU (1) AU753039B2 (en)
CA (1) CA2303901C (en)
DE (1) DE69815872T2 (en)
ES (1) ES2202834T3 (en)
PT (1) PT1019036E (en)
WO (1) WO1999017765A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071230B2 (en) * 1997-10-02 2006-07-04 Board Of Trustees Of Southern Illinois University Therapeutic use of D-methionine to reduce the toxicity of noise
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
NZ531936A (en) * 2001-09-24 2006-10-27 Tosk Inc Reduced toxicity cisplatin formulations and their use for treating a host suffering from a cellular proliferative disease condition
US7700134B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Prevention of cisplatin induced deafness
US20050101534A1 (en) * 2002-11-13 2005-05-12 Sepracor, Inc. Compositions and methods for treating or preventing hearing impairment
US20050090551A1 (en) * 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
JP2008513455A (en) * 2004-09-14 2008-05-01 モレキュラー セラピューティクス インコーポレーティッド D-methionine formulations with improved biopharmaceutical properties
JP5116662B2 (en) 2005-04-06 2013-01-09 ワシントン ユニバーシティ イン セント ルイス Method for measuring metabolism of nervous system-derived biomolecules in vivo
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
CN101287446A (en) 2005-09-29 2008-10-15 尼克塔治疗公司 Antibiotic formulations, unit doses, kits, and methods
US20070105782A1 (en) * 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
US9770433B2 (en) 2006-01-19 2017-09-26 The Regents Of The University Of Michigan Composition and method for treating tinnitus
US20090155390A1 (en) * 2006-01-19 2009-06-18 Miller Josef M Composition and method of treating temporary and permanent hearing loss
US9919008B2 (en) 2006-01-19 2018-03-20 The Regents Of The University Of Michigan Method for treating age-related hearing loss (ARHL)
US7951845B2 (en) * 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
US9889156B2 (en) 2006-01-19 2018-02-13 The Regents Of The University Of Michigan Method for treating noise-induced hearing loss (NIHL)
USRE46372E1 (en) 2006-01-19 2017-04-25 The Regents Of The Univerity Of Michigan Method for treating hearing loss
US8338397B2 (en) * 2006-01-19 2012-12-25 The Regents Of The University Of Michigan Composition and method of treating side effects from antibiotic treatment
US10238599B2 (en) 2006-01-19 2019-03-26 The Regents Of The University Of Michigan Composition and method for treating congenital cytomegalovirus induced hearing loss
US8927528B2 (en) 2006-01-19 2015-01-06 The Regents Of The University Of Michigan Composition for treating hearing loss
JP2009531461A (en) * 2006-03-28 2009-09-03 ノバス インターナショナル インク Hair growth promoting composition
US20090111736A1 (en) * 2007-10-29 2009-04-30 Sri International Orally-Absorbed Solid Dose Formulation for Vancomycin
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
JP5457813B2 (en) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 ADPLL circuit, semiconductor device and portable information device
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
EP2854829A1 (en) * 2012-05-30 2015-04-08 Sensorion Methods for treating vestibulotoxicity
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CA2903275A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2015325043B2 (en) 2014-09-30 2021-02-18 Washington University Tau kinetic measurements

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2732400A (en) 1956-01-24 Method of preparing methionine
US4426372A (en) 1980-08-08 1984-01-17 Regents Of The University Of Minnesota Inhibition of undesired effects of platinum(II) compounds
US5002755A (en) 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
US5292773A (en) 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
CA2122342A1 (en) 1992-09-04 1994-03-17 Hironori Kawabata Pharmaceutical composition
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds

Also Published As

Publication number Publication date
ATE243511T1 (en) 2003-07-15
ES2202834T3 (en) 2004-04-01
AU753039B2 (en) 2002-10-03
US6265386B1 (en) 2001-07-24
EP1019036B1 (en) 2003-06-25
EP1019036A1 (en) 2000-07-19
JP2001518499A (en) 2001-10-16
AU6956898A (en) 1999-04-27
WO1999017765A1 (en) 1999-04-15
DE69815872D1 (en) 2003-07-31
DE69815872T2 (en) 2004-07-08
US6187817B1 (en) 2001-02-13
PT1019036E (en) 2003-11-28
CA2303901C (en) 2008-09-09

Similar Documents

Publication Publication Date Title
CA2303901A1 (en) Use of d-methionine to reduce the toxicity of ototoxic drugs, noise, and radiation
Ellis et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
CA2294247A1 (en) Antioxidant enhancement of therapy for hyperproliferative conditions
HRP920632A2 (en) Oral composition for the treatment of inflammatory l deseases
WO1999067284A3 (en) Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
CA2046397A1 (en) Inflammatory bowel disease preventive and curative agents containing zinc l- carnosine salt or complex as active ingredient
TR200003666T2 (en) Formoterol for the prevention, treatment of an acute case of asthma
TW362971B (en) Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2&#39;-halomethylidene derivatives and a S-phase or M-phase specific anti
AU8136394A (en) Controlled release preparation
ES2010226A6 (en) Stable granulocyte colony stimulating factor composition
CA2244253A1 (en) Method for preventing and treating peripheral neuropathy by administering selegiline
CA2368618A1 (en) Method of enhancing the efficacy of anti-tumor agents
CA2108963A1 (en) Compositions and Methods for Therapy and Prevention of Cancer, Aids and Anemia
IL158155A (en) Use of erythropoietin for the preparation of a medicament to ameliorate chemotherapy-induced toxicity
WO2005039554A3 (en) Therapeutic use of methionine for the treatment or prevention of mucositis
WO1997042968A3 (en) Administration of histamine for therapeutic purposes
NO20001828L (en) Method to prevent nephrotoxicity caused by cyclosporins and tacrolimus
CA2265983A1 (en) Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
IL141232A0 (en) Use of camptothecin derivatives, with reduced gastrointestinal toxicity
CA2098593A1 (en) Treatment method for cancer
CA2234936A1 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
EP0476711A3 (en) Use of 5-fluorouracil for the treatment of AIDS
CA2381203A1 (en) Formulations for treating or preventing mucositis
CA2066031A1 (en) Methods for reducing non-target retention of immunoconjugates and metabolites thereof
Schachter et al. Lisuride in the treatment of parkinsonism

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160408